SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
155.20    2.40 (1.57%)
Bid:
155.00
Ask:
155.40
Spread: 0.40 (0.258%)
Market Cap: £888.23m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM Statement

25 Apr 2013 07:00

RNS Number : 1771D
Elementis PLC
25 April 2013
 



 

 

 

25 April 2013

 

 

AGM / Interim Management Statement

 

Elementis plc (ELM.L, "the Company" or "the Group"), the Global Specialty Chemicals Company, today issues its Interim Management Statement for the three months ended 31 March 2013.

 

Commenting on the Company's performance Group Chief Executive, David Dutro, said: "In the first three months of 2013 we have made a solid start to the year, particularly as we are comparing our performance to a very strong quarter in 2012. We continue to benefit from the diverse nature of our business, both in terms of geography and end market. At Elementis we are committed to creating our own growth opportunities in an uncertain economic environment and the Group has a number of exciting growth initiatives that are at an early stage of development, including the new coatings additives plant in North America, as well as the acquisitions of Watercryl in Brazil and Hi-Mar in the US. Each of these should add momentum to our performance as the year progresses. Overall, we anticipate full year earnings will be in line with market expectations."

 

In Specialty Products, sales volumes in the first quarter were 7 per cent higher than the same period last year with good progress in all key business areas.

·; In coatings additives, sales volumes in North America were 3 per cent higher than the previous year, while volumes in Latin America were 134 per cent higher, as each region benefited from the recent acquisitions of Hi-Mar in North America and Watercryl in Latin America. Volumes in Asia Pacific were 4 per cent higher, while in Europe sales volumes grew by 7 per cent as the business continued to succeed in identifying new business opportunities to offset underlying economic weakness.

·; In personal care, sales volumes were 4 per cent higher than the same period last year.

·; Sales volumes in the oil and gas drilling sector improved significantly in the current period compared to the second half of 2012, when an industry inventory adjustment caused a temporary downturn in order patterns. As a result, sales volumes in the first quarter were 61 per cent higher than the average quarterly sales in the second half of 2012 and only 5 per cent below the first quarter of 2012, which was the strongest sales quarter in the business's history.

In Chromium, as expected, first quarter sales were impacted by a scheduled plant maintenance shutdown. The business operates a pro-active maintenance programme, designed to ensure a stable operating performance with extended periods between shutdowns. The previous maintenance shutdown was done during the second half of 2011, so sales in the first quarter of 2012 were unaffected. The most recent maintenance was carried out in the early part of 2013, thereby reducing sales volumes in the first quarter and, as a consequence, sales volumes were 15 per cent lower than the previous year. However, consistent with the strategy for this business of "stable earnings and cash flow", sales for the year as a whole are expected to be similar to 2012.

The Group's balance sheet remains in a strong position and is expected to be in a net cash position at the end of the year.

 

 

Enquiries:

Elementis

+44 (0) 207 408 9300

Brian Taylorson, Finance Director

FTI Consulting

+44 (0) 207 831 3113

Deborah Scott

Matthew Cole

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMDGGDSUUDBGXS
Date   Source Headline
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.